The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ethmozin     ethyl N-[10-(3-morpholin-4...

Synonyms: Ethmosine, Ethmozine, Etmozin, Moricizine HCl, Ethmozine (TN), ...
This record was replaced with 34633.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MORICIZINE


Psychiatry related information on MORICIZINE

  • Ethmozin appears to be a well-tolerated, effective antiarrhythmic agent with a dosage regimen that can promote patient compliance for long-term use [6].

High impact information on MORICIZINE


Chemical compound and disease context of MORICIZINE


Biological context of MORICIZINE

  • At 1 X 10(-2) g.litre-1, ethmozin decreased the rate of rise of phase 0, and slightly reduced action potential amplitude [13].
  • Ethmozine did not significantly change the baseline heart rate, blood pressure, and QTc interval from the initial drug-free values [14].
  • Alterations in lipid metabolism and cellular morphology in the liver of female rats treated with ethmozine [15].
  • Ethmozine had no effect on radionuclide ejection fraction (25.5 +/- 12.7% to 28.2 +/- 13.8%) or cardiac index (2.4 +/- 0.7 to 3.0 +/- 0.6 ml/min/m2) and caused no significant changes in mean aortic, right atrial, pulmonary arterial, or pulmonary capillary wedge pressures [16].
  • No change was observed in the oral pharmacokinetics of ethmozine following a single intravenous dose of digoxin, as indicated by the area under the plasma concentration versus time curve, Cmax or Tmax [17].

Anatomical context of MORICIZINE

  • Ethmozin had a minor and variable vagolytic action but significantly (p less than 0.05) reduced the sinus node response to sympathetic nerve stimulation [7].
  • Ethmozine prolonged the ventricular effective refractory period in normal and infarcted myocardium, and impaired depressed conduction in ischaemically damaged tissue [5].
  • Ethmozin (3 to 5 mg/kg-1 i.v.) markedly increased conduction delay in the ischaemic zone of the left ventricle during acute coronary artery occlusion [13].
  • Antiarrhythmic effects of ethmozin in cardiac Purkinje fibers: suppression of automaticity and abolition of triggering [18].
  • We conclude that ethmozin blocks INa in Purkinje cells in both a non-use-dependent and a use-dependent manner and that the guarded receptor model is useful in describing the use-dependent block [19].

Associations of MORICIZINE with other chemical compounds


Gene context of MORICIZINE

  • The patients were given for one week ethmozine and then again for one week etacizine, during which periods they were followed echocardiographically, with pressure measurement in the pulmonary artery (PAP) and in the right atrium (RAP) [23].

Analytical, diagnostic and therapeutic context of MORICIZINE


  1. Efficacy and safety of moricizine in patients with ventricular tachycardia: results of a placebo-controlled prospective long-term clinical trial. Pratt, C.M., Wierman, A., Seals, A.A., English, L., Leon, C., Young, J.B., Quinones, M.A., Roberts, R. Circulation (1986) [Pubmed]
  2. Comparative effect of disopyramide and ethmozine in suppressing complex ventricular arrhythmias by use of a double-blind, placebo-controlled, longitudinal crossover design. Pratt, C.M., Young, J.B., Francis, M.J., Taylor, A.A., Norton, H.J., English, L., Mann, D.E., Kopelen, H., Quinones, M.A., Roberts, R. Circulation (1984) [Pubmed]
  3. Ethmozin, a new antiarrhythmic drug for suppressing ventricular premature complexes. Podrid, P.J., Lyakishev, A., Lown, B., Mazur, N. Circulation (1980) [Pubmed]
  4. Complex ventricular arrhythmias associated with the mitral valve prolapse syndrome. Effectiveness of moricizine (Ethmozine) in patients resistant to conventional antiarrhythmics. Pratt, C.M., Young, J.B., Wierman, A.M., Borland, R.M., Seals, A.A., Leon, C.A., Raizner, A., Quinones, M.A., Roberts, R. Am. J. Med. (1986) [Pubmed]
  5. Electrophysiological mechanisms of action of ethmozine that explain its antiarrhythmic efficacy in the late stage of experimental myocardial infarction in dogs. Aidonidis, I., Egel, E., Hilbel, T., Rizos, I., Kuebler, W., Brachmann, J. Eur. Heart J. (1994) [Pubmed]
  6. Ethmozin: a new antiarrhythmic agent developed in the USSR. Efficacy and tolerance. Morganroth, J., Pearlman, A.S., Dunkman, W.B., Horowitz, L.N., Josephson, M.E., Michelson, E.L. Am. Heart J. (1979) [Pubmed]
  7. Differential modulation of autonomic activity by ethmozin and ethacizin (analog of ethmozin) on the canine sinus node and atrioventricular junction. Urthaler, F., Rosenshtraukh, L.V., Hageman, G.R., Anjukhovsky, E.P., James, T.N. J. Am. Coll. Cardiol. (1986) [Pubmed]
  8. Cimetidine inhibition of ethmozine metabolism. Biollaz, J., Shaheen, O., Wood, A.J. Clin. Pharmacol. Ther. (1985) [Pubmed]
  9. Newer antiarrhythmic drugs in children. Moak, J.P., Smith, R.T., Garson, A. Am. Heart J. (1987) [Pubmed]
  10. Comparison of ethmozine to propranolol and the combination for ventricular arrhythmias. Butman, S.M., Knoll, M.L., Gardin, J.M. Am. J. Cardiol. (1987) [Pubmed]
  11. Effect of moricizine hydrochloride in reducing chronic high-frequency ventricular arrhythmia: results of a prospective, controlled trial. Singh, S.N., DiBianco, R., Gottdiener, J.S., Ginsberg, R., Fletcher, R.D. Am. J. Cardiol. (1984) [Pubmed]
  12. Effects of magnesium and ethmozin on ventricular tachycardia induced by ouabain and ventricular pacing in conscious dogs with complete atrioventricular block. Fazekas, T., Vos, M.A., Leunissen, J.D., Wellens, H.J. Acta physiologica Hungarica. (1993) [Pubmed]
  13. Electrophysiological effects of ethmozin on canine myocardium. Ruffy, R., Rozenshtraukh, L.V., Elharrar, V., Zipes, D.P. Cardiovasc. Res. (1979) [Pubmed]
  14. Antiarrhythmic efficacy of ethmozine in patients with ventricular tachycardia as determined by programmed electrical stimulation. Miura, D.S., Wynn, J., Torres, V., Laux, B., Keefe, D., Somberg, J.C. Am. Heart J. (1986) [Pubmed]
  15. Alterations in lipid metabolism and cellular morphology in the liver of female rats treated with ethmozine. Vincent, D.R., Gillies, P.J., Lee, K.P., Wood, C.K., Arthaud, L.E. Toxicol. Appl. Pharmacol. (1988) [Pubmed]
  16. Ethmozine: electrophysiology, hemodynamics, and antiarrhythmic efficacy in patients with life-threatening ventricular arrhythmias. Dorian, P., Echt, D.S., Mead, R.H., Lee, J.T., Lebsack, C.S., Winkle, R.A. Am. Heart J. (1986) [Pubmed]
  17. Assessment of the potential pharmacokinetic interaction between digoxin and ethmozine. MacFarland, R.T., Moeller, V.R., Pieniaszek, H.J., Whitney, C.C., Marcus, F.I. Journal of clinical pharmacology. (1985) [Pubmed]
  18. Antiarrhythmic effects of ethmozin in cardiac Purkinje fibers: suppression of automaticity and abolition of triggering. Dangman, K.H., Hoffman, B.F. J. Pharmacol. Exp. Ther. (1983) [Pubmed]
  19. Use-dependent block of sodium current by ethmozin in voltage-clamped internally perfused canine cardiac Purkinje cells. Makielski, J.C., Undrovinas, A.I., Hanck, D.A., Sheets, M.F., Nesterenko, V.V., Alpert, L.A., Rosenshtraukh, L.V., Fozzard, H.A. J. Mol. Cell. Cardiol. (1988) [Pubmed]
  20. Influence of action potential duration and resting potential on effects of quinidine, lidocaine and ethmozin on Vmax in guinea-pig papillary muscles. Jurevicius, J., Muckus, K., Macianskiene, R., Chmel-Dunaj, G.N. J. Mol. Cell. Cardiol. (1991) [Pubmed]
  21. A patch clamp study of the action of ethacyzine on the rapid inward sodium current in single rat heart muscle cells. Schubert, B., Bodewei, R., Hering, S., Wollenberger, A. Eur. J. Pharmacol. (1986) [Pubmed]
  22. Interactions of antiarrhythmics with artificial phospholipid membranes. Voigt, W., Mannhold, R., Limberg, J., Blaschke, G. Journal of pharmaceutical sciences. (1988) [Pubmed]
  23. Echocardiographic assessment of the haemodynamic effect of ethmozine and its diethylamine analogue etacizine in patients with heart failure. Ageev, F.T., Sergakova, L.M., Niu-Tian-de, G.B., Mareev, V.Y. Cor et vasa. (1986) [Pubmed]
  24. Characterization of the rate-dependent effects of ethmozine on conduction, in vivo, and on the sodium current, in vitro, in the newborn heart. Liu, W., Clarkson, C.W., Yamasaki, S., Chang, C., Stolfi, A., Pickoff, A.S. J. Pharmacol. Exp. Ther. (1992) [Pubmed]
  25. Electrophysiologic effects of ethmozin in patients with ventricular tachycardia. Mann, D.E., Luck, J.C., Herre, J.M., Magro, S.A., Yepsen, S.C., Griffin, J.C., Pratt, C.M., Wyndham, C.R. Am. Heart J. (1984) [Pubmed]
  26. Serum digoxin concentrations during ethmozine antiarrhythmic therapy. Kennedy, H.L., Sprague, M.K., Redd, R.M., Wiens, R.D., Blum, R.I., Buckingham, T.A. Am. Heart J. (1986) [Pubmed]
WikiGenes - Universities